Ebola treatments given after a possible exposure could change how outbreaks are fought. But a new debate zeroes in on an uncomfortable detail in one such trial: the very people running toward the outbreak, health workers, lab staff, burial teams, could end up getting a placebo if they’re exposed on the job.
The EBO-PEP trial, currently recruiting during the Bundibugyo virus disease outbreak in the DRC and Uganda, is evaluating obeldesivir, an oral antiviral, as post-exposure prophylaxis for Ebola. Described as the first controlled evaluation of an oral antiviral for this purpose, it could let affected communities access preventive treatment far more quickly than current approaches allow. But writing in Nature Africa, a group of researchers and ethics experts argues the trial’s protocol has a critical blind spot: frontline responders who sustain high-risk occupational exposures remain eligible for randomization to placebo.
Protecting the Frontline
The authors aren’t arguing against the trial, they call EBO-PEP one of the most important advances in Ebola research in years. Their concern is narrower: health care workers, lab personnel, and burial teams are exposed because of a job they’ve taken on, not through ordinary household contact, and the protocol treats the two the same.
The argument rests on reciprocity, the idea that society owes something back to people who knowingly accept elevated risk on others’ behalf, and duty of care, which obligates employers to minimize foreseeable occupational risks. These principles already justify protective equipment and occupational health services; the authors argue they should also shape access to investigational drugs with established human safety data.
Hundreds of health workers died during the 2013-2016 West African epidemic. In the current outbreak, 151 health care workers were among 3,605 confirmed cases as of August 1, 2026. The authors also cite a biological distinction: needlestick exposures may deliver larger viral doses than typical community exposures, and higher viral loads are linked to worse outcomes, though direct human evidence connecting exposure route to outcome remains limited.
Prioritize Healthcare Workers as a Special Population
Accommodating this group is feasible. EBO-PEP already carves out non-randomized enrollment for pregnant women and children under 12, given their own safety considerations; a similar pathway could work for occupational exposures without compromising the trial’s scientific goals. Where that isn’t possible, WHO’s Monitored Emergency Use of Unregistered and Investigational Interventions framework, already used in past Ebola and Marburg outbreaks, offers an existing route for emergency access outside randomized research.
There’s a longer-term stake too: outbreak control depends on a workforce willing to take dangerous assignments, and that willingness can erode if workers feel their exposure is treated no differently than anyone else’s. The authors cite evidence from West Africa showing senior health workers consistently favored prioritizing responders for investigational therapeutics, citing reciprocity as their main justification.
Sources and further reading:
Protecting those who protect us: the ethics of Ebola post-exposure trials — Nature Africa
This article was researched and sourced by Global Biodefense editors and reported with Claude AI assistance for drafting and editing.